Posted by Michael Wonder on 09 Apr 2019
PhaseBio receives FDA breakthrough therapy designation for PB2452 for the reversal of the anti-platelet activity of ticagrelor
8 April 2019 - In Phase 1 clinical trial, PB2452 provided immediate and sustained reversal of ticagrelor anti-platelet effects.
PhaseBio Pharmaceuticals today announced that the U.S. FDA has granted breakthrough therapy designation for PB2452, a novel reversal agent for the anti-platelet drug ticagrelor.
The breakthrough therapy designation for PB2452 was supported by Phase 1 trial results, in which PB2452 achieved immediate and sustained reversal of ticagrelor’s antiplatelet effects. The results from this trial were recently published in the New England Journal of Medicine and presented in a featured clinical research session at the American College of Cardiology’s 68th Scientific Session.
